Gilead CEO Dan O’Day uncorked some solid Q2 results on Tuesday, touting a surge in Yescarta and Trodelvy sales and an uptick in demand for HIV med Biktarvy. Will sinking Covid sales spoil the party?
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,